OS Therapies (NYSEAMERICAN:OSTX) Trading Up 3.6% – What’s Next?

OS Therapies Incorporated (NYSEAMERICAN:OSTX) was up 3.6% during trading on Thursday . The company traded as high as $1.46 and last traded at $1.43. Approximately 342,809 shares changed hands during mid-day trading, a decline of 27% from the average daily volume of 470,165 shares. The stock had previously closed at $1.38.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on OSTX shares. Zacks Research raised OS Therapies from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 11th. D. Boral Capital reissued a “buy” rating and set a $20.00 target price on shares of OS Therapies in a research report on Thursday, February 5th. Finally, Lake Street Capital lowered their price target on shares of OS Therapies from $18.00 to $17.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $18.50.

OS Therapies Stock Up 2.8%

The company has a market capitalization of $51.76 million, a PE ratio of -1.79 and a beta of -3.79. The firm’s 50-day moving average is $1.40 and its 200-day moving average is $1.77.

Hedge Funds Weigh In On OS Therapies

A number of large investors have recently modified their holdings of OSTX. State Street Corp grew its position in OS Therapies by 16.3% during the fourth quarter. State Street Corp now owns 58,500 shares of the company’s stock valued at $82,000 after acquiring an additional 8,200 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of OS Therapies by 31.1% in the 4th quarter. Geode Capital Management LLC now owns 246,038 shares of the company’s stock worth $344,000 after acquiring an additional 58,350 shares during the last quarter. Millennium Management LLC purchased a new stake in shares of OS Therapies in the 3rd quarter valued at $183,000. Virtu Financial LLC grew its holdings in shares of OS Therapies by 252.0% during the 3rd quarter. Virtu Financial LLC now owns 75,801 shares of the company’s stock valued at $149,000 after purchasing an additional 54,269 shares during the last quarter. Finally, Two Sigma Investments LP bought a new position in shares of OS Therapies during the 3rd quarter valued at $169,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.